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Summary 
Using sheep erythrocytes  and liposomes,  an inhibitory effect of gangliosides has been shown 
on the activation of the alternative pathway of complement. However, in studies using human 
erythrocytes, we found that gangliosides had hemolytic activity that was possibly mediated through 
activation of the alternative pathway. Pretreatment of human erythrocytes obtained from healthy 
volunteers or paroxysmal nocturnal hemoglobinuria (PNH) patients with a ganglioside mixture 
purified from human erythrocytes enhanced their susceptibility to homologous human complement, 
and resulted in dose-dependent hemolysis. The enhancement was more marked in PNH erythrocytes 
than control cells. Protease treatment of the ganglioside mixture did not change its hemolytic 
activity, but sialidase treatment abolished the activity. Among the major erythrocyte gangliosides, 
II3NeuAc-LacCer  (GM3)  was  the most  potent  hemolytic agent.  Gangliosides  purified  from 
bovine brain were also active, while neither nonsialylated glycosphingolipids, the ceramide moiety, 
or sialic acid alone were active. Sialic acid residues in the ganglioside molecules were essential 
to this activity, but the amount of the residue or the source of the gangliosides  seemed not 
to be important. Several  treatments inhibiting the alternative but not classical  complement pathway 
markedly reduced the ganglioside hemolytic activity. This novel bioactivity of gangliosides was 
thus suggested  to be mediated partly by activation  of the alternative pathway. 
G 
angliosides  are  sialylated  glycosphingolipids  (GSLs)  1 
that are functionally located on the outer cell membrane 
(1). GSLs are well known to participate in various membrane- 
related biological functions  that  are  associated with  cell 
growth, development, differentiation, and transformation (2, 
3). However, the molecular mechanisms of the involvement 
of GSLs in cellular membrane function are not yet dear. Ex- 
tensive studies have elucidated new biological functions of 
GSLs, such as the modulation of cell growth (4, 5), induc- 
tion of cell differentiation  (6), modulation of the immune 
response (7, 8), and inhibition of viral infection (9), when 
GSLs are added exogenously to cell culture. In each case, the 
exogenous GSLs are first inserted into and accumulated in 
1 Abbreviations used in this paFer: DAF, decay-accderating factor;  GSL, 
glycosphingolipid; PNH, paroxysmal nocturnal hemaglobinuria. GSLs were 
abbreviated according to the recommendations of the International Union 
of Pure and Applied Chemistry (IUPAC) and the International Union 
of Biochemistry (IUB) (42), or the nomenclature system of Svennerholm 
(43). 
the lipid layer of the cell membrane (10-14), after which.they 
affect membrane function (3-6, 11, 15). An intensive search 
for new bioactivities  that arise from the interaction of ex- 
ogenously added GSLs with the functional constituents of 
cell membranes (4, 11, 16-18) might provide some clues to 
help our understanding of the critical role of endogenous GSLs 
in physiological  membrane functions. We have recently demon- 
strated the altered expression of membrane gangliosides in 
erythrocytes  from  patients  with  paroxysmal  nocturnal 
hemoglobinuria (PNH) (19). During our exploration of the 
physiological  significance  of ganglioside accumulation in PNH, 
we also discovered a hemolytic activity of gangliosides that 
has the potential to be used to enhance our understanding 
of the physiological role of membrane GSLs. 
Materials and Methods 
Chemicals.  All organic solvents used were of analytical  grade. 
DEAE Sephadex  A-25 was obtained from Pharmacia  Fine Chem- 
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described previously (20). Iatrobeads (activated silicic acid, 6RS- 
8060) were purchased  from Iatron Laboratories  Inc. (Tokyo,  Japan). 
Precoated high-performance thin-layer plates (Silica Gel 60, 0.25 
mm thick) were purchased  from E. Merck (Darmstadt, Germany), 
Sialic acid (N-acetylneuraminic acid) was donated by Meet Co, 
(Tokyo, Japan). Beef brain ceramide was purchased from Serdary 
Research Laboratories (Ontario, Canada). EDTA and EGTA were 
purchased from Nacalai Tesque (Kyoto, Japan). The ganglioside 
mixture  used, as well as IV3NeuAc, II3NeuAc-Gg~Cer (GDla), 
were purified from bovine brain in our laboratory by the method 
described below. 
Extraction  and Purification  of GSLs  from Erythrocytes.  Gangliosides 
and neutral GSLs were purified by the methods described previ- 
ously (19, 21, 22). In brief, erythrocyte membranes were isolated 
by lysing erythrocytes from healthy volunteers with 0.05% acetic 
acid and total lipids were extracted from the membranes with or- 
ganic solvents. After the removal  of  glyceroglycolipids  by mild alka- 
line hydrolysis,  GSLs were then separated into neutral and acidic 
(ganglioside) fractions by DEAE-Sephadex A-25 column chroma- 
tography, and individual GSLs were further purified by Iatrobeads 
linear-gradient column chromatography (23). Purified glycolipids 
were then analyzed using TIC and quantitatively determined by 
densitometric analysis in comparison with standard glycolipids. 
Hemolysis  Assay.  Ham's acidified  serum test (24) was modified 
to assay the hemolytic activity of gangliosides or neutral GSLs. 
Briefly, erythrocytes were obtained from the peripheral blood of 
healthy volunteers  or PNH patients after consent was given, washed 
three times with saline, and incubated in saline at 37~  for 5 min 
with various  concentrations of  gangliosides  or neutral GSLs.  These 
pretreated erythrocytes were washed thoroughly  with saline  to re- 
move unbound glycolipids  and were then adjusted to 3  x  109/ml 
in saline. 50/zl of the pretreated erythrocytes (1.5 x  10  ~  cells) was 
incubated  at 37~  for 60 rain with 500 #1 of  complement-containing 
serum obtained  just before  use from blood type (ABO, Rh)-matched 
healthy volunteers.  Differing from Ham's test, fresh serum was not 
acidified in our assays. The extent of hemolysis was evaluated by 
measuring the hemoglobin liberated into the supernatant using a 
spectrophotometer (DU  series 60;  Beckman Instruments  Inc., 
FuUerton, CA) at 540 nm. Each assay  was performed in duplicate 
or triplicate. 
To examine the involvement of complement in the process of 
hemolysis, inactivation of serum complement was performed by 
heating at 56~  for 30 min or chelating with EDTA and EGTA 
(both 5 raM) (25-27). A combination of both 10 mM EGTA and 
5 mM MgC12 was used for the selective  inhibition of the classical 
pathway of complement (25-27).  The gangLioside fraction was 
treated with protease from Stapt~lococcus  aureus strain V8 (Sigma 
Chemical Co., St. Louis, MO) at 37~  for 2 h to inactivate pos- 
sible protein contaminants. 
Flow Cytometric  Analysis.  Erythrocytes pretreated with a gan- 
glioside mixture of erythrocytes were incubated with mouse mAb 
against II3NeuAc-LacCer (GM3) (Mectolone-015; Meet  Co.)  at 
4~  for 30 min, and subsequently labeled with FITC-conjugated 
goat anti-mouse Ig (Zymed Laboratories  Inc., San Francisco, CA) 
at 4~  for 30 min. They were then analyzed by laser fluorometry 
(FACScan  |  Becton Dickinson & Co., Mountain View, CA) as de- 
scribed previously (11, 15). The membrane expression of decay- 
accelerating  factor (DAF) by erythrocytes  was also fluorocytometri- 
cally analyzed as described previously (19). 
Results 
TIC of C,  angliosides Purified  from Human Erythrocytes.  Fig. 
I  shows the results of TLC of gangliosides.  As is already 
well  known,  the  major  gangliosides  found  were  G~t3, 
IV3NeuAc-nLc4Cer  (2-3SPG),  IV3NeuAc-Gg4Cer  (G~I), 
and IV6NeuAc-nLc4Cer (2-6SPG) in erythrocyte membranes 
(lane  1)  (28),  and  GM3, GM1, and  Gma in bovine brain 
(lane  5).  GM3 (lane  2)  and 2-3SPG  (lane  3)  were isolated 
individually as the major gangliosides found in human ery- 
throcytes. 
Hemolysis Assay.  Hemolytic activity is often determined 
by the percent hemolysis calculated from the population of 
hemolyzed cells. For the sensitive detection of slight hemol- 
ysis, we used the change in optical density of the supernatant 
during incubation. The optical density after the complete 
hemolysis of 1.5  x  10  s erythrocytes with 0.02% acetic acid 
was "~4.0, and this value corresponded to 100%  hemolysis. 
Using several different concentrations of erythrocytes, the re- 
lation between optical density and percent hemolysis was then 
Figure 1.  TLC of gangliosides  purified  from human erythrocytes  or 
bovine brain. Gangliosides  were separated  with a solvent  system  of chlo- 
roform/methanol/0.5%  aqueous CaCl2 (55:45:10 by vol) and visualized 
with resorcinol-HC1  (21). (Lanes I-3) Ganglioside  mixture, GM3, and 
2-3SPG from  human  erythrocytes,  respectively;  (lane  4) GM3, GM2, Gin, 
GD3, GDla, Gnlb, and GTlb as marker gangliosides  from bovine brain; 
(lane 5) ganglioside  mixture from bovine brain. 
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Figure 2.  Correlation  between 
optical density  (ODs~o) and per- 
cent hemolysis  in the hemolysis 
assay. The complete  hemolysis  of 
1.5  x  10  s erythrocytes  obtained 
from healthy  volunteers (Q) or 
PNH patients  ((9) corresponds  to 
100% hemolysis. Using several 
numbers of  erythroc7~ the curve 
was determined  as described  in the 
text. 
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of 0-50% hemolysis, and the standard curve obtained with 
PNH erythrocytes was almost identical to that for control 
erythrocytes (Fig. 2). On the basis of this linear relation, the 
optical density was converted to percent hemolysis in the sub- 
sequent  hemolysis assays. 
Ganglioside-treated  erythrocytes  obtained  from  healthy 
volunteers or PNH patients showed a dose-dependent increase 
in sensitivity to complement-containing  serum, resulting in 
increased hemolysis (Fig. 3). PNH erythrocytes were origi- 
nally  sensitive  to  complement  (see the  percent  hemolysis 
without ganglioside treatment in Fig. 3), and the ganglioside- 
treated PNH cells (Fig.  3, a and b) showed even more en- 
hancement  of their  susceptibility to  complement-contain- 
ing serum when compared with ganglioside-treated control 
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Figure 3.  Enhanced  hemolysis of ganglioside-treated human erythro- 
cytes. Erythrocytes  obtained from nine healthy volunteers (@) and eight 
PNH patients (O) were incubated with O-8-#M (12/~g/ml) concentra- 
tiom ofa ganglioside  mixture isolated  from human erythrocytes. (a) Erythro- 
cytes  with a 98% DAF-negative  population from a PNH patient; (b) erythro- 
cytes with a 15-70% DAF-negative  population from seven  PNH patients; 
(c) control erythrocytes from nine healthy volunteers. 
erythrocytes from healthy volunteers (Fig.  3 c). The gangli- 
oside-induced enhancement of susceptibility of control erythro- 
cytes to complement was weak but reproducible.  Ganglio- 
sides at <2/~M (3/~g/ml) could also clearly enhance hemolysis 
in some cases of PNH. Pretreatment with 8/zM (12/zg/ml) 
ganglioside mixture for 5 min induced, respectively, 20%, 
2-5%,  and  1-2%  enhancement  of the hemolysis of PNH 
erythrocytes that were 98% DAF-negative from a PNH pa- 
tient  with  coexisting C9 deficiency (Fig.  3 a)  (29),  PNH 
erythrocytes that were 15-70% DAF negative (Fig. 3 b), and 
control erythrocytes from healthy volunteers (Fig. 3 c). Fig. 4 
shows the dependency of ganglioside-induced hemolysis on 
the duration of pretreatment of erythrocytes with 8 #M gan- 
glioside mixture. The hemolytic effect reached its maximum 
level within 20 rain in control erythrocytes (Fig.  4 b) and 
increased with  time in PNH erythrocytes (Fig.  4 a). 
Fig. 5 shows the hemolytic activity of the individual gan- 
gliosides. GM3 purified from human erythrocytes possessed 
a potent activity, whereas 2-3SPG from human erythrocytes 
or GDla from bovine brain were not biologically active. The 
ganglioside mixture obtained from bovine brain also showed 
a marked hemolytic activity at similar doses to those oferyth- 
rocyte gangliosides  (data not  shown). 
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Figure 4.  Dependency  of hemo- 
.  lysis on the duration of ganglio- 
side treatment. Eryt~  from 
a healthy volunteer (b) or a PNH 
patient (a) were  treated  with 8/zM 
6'0  (12/zg/ml)  ganglioside mixture 
for 0-60 min at 37~  as described 
in the text. 
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Figure 5.  Hemolytic  activity  of 
individual gangliosides. Erythro- 
cytes with a 5% DAF-negative 
population were incubated for 5 
min at 37~  with GM3 (O) and 
2-3SPG (A) purified from human 
erythrocytes, GDla purified from 
bovine  brain (A), or the ganglio- 
side mixture obtained from hu- 
man erythrocytes (Q). All gan- 
gliosides were used at 8 #M. 
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any hemolytic activity at 8/~M (data not shown). Neuramin- 
idase treatment of gangliosides  inhibited their hemolytic effect. 
Heating and protease treatment of the ganglioside mixture 
to inactivate possible protein contaminants did not change 
its hemolytic activity (data not shown). To investigate the 
involvement of complement in ganglioside-induced  hemol- 
ysis, several types of pretreatment of complement-containing 
serum were performed (Fig. 6). Heating at 56~  for 30 min 
(Fig. 6, column 2) and the use of both 5 mM EDTA and 
5 mM EGTA (Fig. 6, column 3) reduced, respectively, the 
hemolysis to 50% and 45% of the control level achieved with 
untreated serum (Fig. 6, column 1). Serum obtained  from 
a patient with C9 deficiency (Fig. 6, column 5) (29) also re- 
duced the hemolysis to 44% of the control level. However, 
addition of both 10 mM EGTA and 5 mM MgC12 (which 
inhibits the classical but not alternative pathway of comple- 
ment) did not reduce hemolysis (data not shown). 
Flow Cytometric Analysis of Ganglioside-treated  Erythrocytes. 
After ganglioside treatment of erythrocytes,  we performed 
flow cytometric analysis with anti-glycolipid (GM3) antibody, 
which showed that the ganglioside-treated erythrocytes were 
stained more intensely than the untreated erythrocytes (data 
not shown). 
Discussion 
We detected and investigated a new biological activity of 
gangliosides. A ganglioside mixture that was isolated from 
human erythrocytes induced hemolysis in a dose-dependent 
manner when added to human erythrocytes. PNH erythro- 
cytes are susceptible to complement (30, 31) due to the lack 
of complement regulatory proteins (32-34), and they showed 
more enhancement of their susceptibility  to complement- 
containing serum than the control erythrocytes.  The dis- 
crepancy in the time course of ganglioside-mediated hemol- 
ysis between the control and PNH erythrocytes may suggest 
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Figure 6.  Effects  of various me- 
thods of complement  inhibition 
on ganglioside-induced  hemolysis. 
Erythrocytes with a 17% DAF- 
negative  population were  incu- 
bated with 8 ~tM (12/tg/ml) gan- 
glioside mixture (columns  1-5) 
and then hemolyzed with comple- 
ment-containing serum or with 
serum pretreated in various ways 
to inactivate complement.  (Col- 
umn I) Untreated serum; (column 
2) serum heated at 56~  for 30 
rain; (column 3)  serum  treated 
with 5 mM of both EDTA and 
EGTA;  (column 4)  serum  free; 
(column 5) C9-deficient serum; 
(column 6) background (serum 
and ganglioside free). Each value 
represents the mean of triplicate 
determinations,  and a second ex- 
periment gave similar results. 
that the maximum level of ganglioside hemolytic activity de- 
pends on the size of the population of labile erythrocytes sus- 
ceptible to complement attack. Several  methods of treatment 
of serum to inactivate complement significantly reduced the 
extent  of ganglioside-induced  hemolysis.  Moreover,  C9- 
deficient serum also reduced the hemolysis. Inhibition of the 
classical but not the alternative pathway of complement did 
not decrease the hemolysis. Antibody-dependent cytolysis is 
known to be associated with the classical pathway of com- 
plement (35). However, we could not detect serum antibodies 
directed against either gangliosides or erythrocytes using TLC 
immunostaining (19) or  laser  fluorocytometry (data  not 
shown). These results thus suggest that ganglioside-induced 
hemolysis occurs at least partly through activation of the al- 
ternative pathway of complement, but is not antibody de- 
pendent. 
The following findings also suggested the involvement of 
additional mechanisms in the hemolytic process. Even in the 
absence of complement-containing serum, gangliosides still 
induced hemolysis dose dependently but weakly. Inhibition 
of the activation  of complement with chelating agents or 
heating was remarkably effective in reducing hemolysis, but 
did not completely eliminate it. Also, gangliosides induced 
the hemolysis of even control erythrocytes,  which express 
sufficient complement-regulatory membrane proteins to pre- 
vent hemolytic attack by complement. Finally, even in the 
presence of C9 deficiency serum,  gangliosides still induced 
hemolysis. These results all imply the involvement of other 
mechanisms in ganglioside-induced hemolysis in addition to 
complement activation. 
We investigated the possible presence of contaminants with 
a hemolytic activity, especially  proteins or neutral glycolipids, 
in ganglioside mixture. Pretreatment of the mixture using 
proteases or heat did not produce any change in the hemo- 
lytic activity. Organic solvents like chloroform and meth- 
anol, which denature proteins,  were actually used in puri- 
fication of the gangliosides, so it is quite unlikely that any 
proteins with hemolytic activity survived in the ganglioside 
mixture. Neutral GSLs isolated from human erythrocytes did 
not have any hemolytic activity, even at higher doses of up 
to 200 #M. Alkaline hydrolysis used in the purification  of 
gang/iosides could eliminate lyso-phospholipids  that are known 
to possess hemolytic activity. Thus, our results suggest that 
only the gangliosides in the mixture possessed any hemo- 
lytic activity. The structural difference between gangliosides 
and neutral GSLs is solely the presence of sialic acid residues 
in the former, suggesting that these residues are more crit- 
ical than the other carbohydrate or ceramide moieties of the 
gangliosides with respect to the hemolytic activity. To confirm 
this new biological activity and examine the structure-activity 
relationships of gangliosides, we isolated the major ganglio- 
sides GM3 and 2-3SPG, which comprise >80% of the gan- 
gliosides in human erythrocytes (28). GM3 showed a potent 
hemolytic activity, while 2-3SPG (the most abundant gan- 
glioside in erythrocytes) did not show any hemolytic activity. 
A ganglioside mixture isolated from bovine brain also pos- 
sessed remarkable hemolytic activity. Bovine brain GI)la did 
1388  Ganglioside-induced Hemolysis of Human Erythrocytes not show any hemolytic activity. Thus, the two ganglioside 
mixtures and GM3 itself from human erythrocytes were in- 
dicated to possess a potent hemolytic activity, and the sialic 
acid content of the molecules seemed not to be critical  to 
the production of hemolysis. These results suggest that nei- 
ther ganglioside-induced hemolysis was due to artifidal damage 
using high levels of lipids, nor that the hemolysis required 
sialic acid simply for the solubility of the lipids. 
Regarding the mode of action of the exogenously added 
gangliosides,  fluorocytometric analysis suggested that they 
were functionally incorporated into the erythrocyte mem- 
brane. The incorporation of gangliosides into cell membranes 
has been reported to be essential in their biological activities 
at varying doses (10-14). Thus, the next problem is to clarify 
how the incorporated gangliosides induced hemolysis.  We 
have suggested the possible  involvement of the alternative 
pathway in the production of hemolysis. There have already 
been reports that gangliosides regulate the activation of the 
alternative pathway (36-38), but they were actually reported 
to inhibit the activation of the alternative pathway, although 
our findings suggested a quite different conclusion. This dis- 
crepancy may be partly explained by differences in the ex- 
perimental conditions. First, the molecular species and doses 
of the gangliosides used were different. Next, the previous 
studies evaluated the effects of gangliosides by measuring C3 
conversion on the surface of ganglioside-containing  liposomes 
or animal erythrocytes like sheep erythrocytes. In contrast, 
we  assessed the  hemolysis of ganglioside-treated human 
erythrocytes. Thus, the possibility of conformational differ- 
ences in the membrane localization of gangliosides when they 
are incorporated into liposomes or intact human blood cells 
can be suggested (39-41).  In particular, intact cells and above 
all human erythrocytes possess both well-known and per- 
haps unknown complement-regulatory membrane proteins 
in contrast to liposomes. It seems likely that the presence 
of such complement regulatory proteins has various effects 
on the activation of complement. The different results in var- 
ious studies may thus reflect the presence of several sorts of 
complement-regulatory  membrane proteins, the functions of 
which could be modulated by gangliosides. In fact, the selec- 
tive and functional interaction of gangliosides (especially 
GM3) with membrane proteins has been reported previously 
(4,  16, 41). Accordingly, we propose that the exogenously 
added gangliosides  were first inserted into the erythrocyte 
membrane where they interacted with certain membrane 
constituents  that  might  restrain  complement activation, 
abolished this restriction, and produced hemolysis after acti- 
vation of the alternative pathway. Interestingly, ganglioside- 
treated white blood cells also became susceptible to comple- 
ment-containing serum (data not shown). Further studies are 
still required to clarify the molecular mechanisms of ganglio- 
side-induced activation of the alternative pathway to produce 
hemolysis. 
This is apparently the first report of a hemolytic effect of 
gangliosides on human erythrocytes. The use of intact PNH 
erythrocytes with increased susceptibility to complement and 
the establishment of a sensitive method for the quantitation 
of hemolytic activity using spectrophotometry enabled us to 
reproducibly detect this novel hemolytic activity of ganglio- 
sides. We have previously reported the increased expression 
of gangliosides in the membranes of PNH erythrocytes (19). 
These findings, taken together, suggest that the increased ex- 
pression of membrane gangliosides in PNH erythrocytes may 
lead to abnormal hemolysis. 
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